About ONCOtracker
ONCOtracker is a company based in West Hollywood (United States) founded in 2014 by James R Berenson. ONCOtracker has raised $1.3 million across 3 funding rounds. ONCOtracker offers products and services including Serum BCMA Test, Immunoassays, Pre-clinical Drug Development, and Biospecimens. ONCOtracker operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
- Headquarter West Hollywood, United States
- Founders James R Berenson
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Oncotracker, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.3 M (USD)
in 3 rounds
-
Latest Funding Round
$150 K (USD), Seed
Feb 13, 2020
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ONCOtracker
ONCOtracker offers a comprehensive portfolio of products and services, including Serum BCMA Test, Immunoassays, Pre-clinical Drug Development, and Biospecimens.
Test for monitoring multiple myeloma biomarkers in patients.
Assays for pre-clinical drug development and research.
Support for oncology drug trials and evaluations.
Provision of samples for cancer research studies.
Funding Insights of ONCOtracker
ONCOtracker has successfully raised a total of $1.3M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $150 thousand completed in February 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by ONCOtracker
Investment portfolio details for ONCOtracker
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ONCOtracker
Detailed financials for ONCOtracker
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oncotracker Comparisons
Peer comparison for ONCOtracker
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ONCOtracker
ONCOtracker operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are developed.
|
Detailed competitors of ONCOtracker
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oncotracker
Complete news archive for ONCOtracker
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ONCOtracker
ONCOtracker was founded in 2014 and raised its 1st funding round 2 years after it was founded.
ONCOtracker is headquartered in West Hollywood, United States. It is registered at West Hollywood, California, United States.
James R Berenson is the current CEO of ONCOtracker. They have also founded this company.
ONCOtracker is a funded company, having raised a total of $1.3M across 3 funding rounds to date.
Developer of immune assays for the diagnosis of cancer. The companys diagnostic assay is used for testing multiple myeloma, B-cell malignancies and other related disorders. It includes Serum B-Cell Maturation Antigen (sBCMA) blood test assay, which is used to monitor the tumour and predict the therapeutic outcome of patients with multiple myeloma. It is used to treat chronic lymphocytic leukaemia, B-cell lymphoma and solid tumour.
ONCOtracker's top competitors include Guardant Health, Exact Sciences and Foundation Medicine.
ONCOtracker offers Serum BCMA Test, Immunoassays, Pre-clinical Drug Development, and Biospecimens.